Adolescence combines rapid growth, increasing academic demands, and vulnerability to nutritional imbalance. Menstrual blood loss and restrictive diets can exhaust iron reserves before anemia develops. In oncology, reduced intake, gastrointestinal injury, bleeding, and repeated investigations may intensify this vulnerability. Cognitive complaints are frequently attributed to chemotherapy, sleep disruption, or psychological distress; potentially reversible nutritional contributors therefore deserve consideration without displacing these established explanations.
To evaluate latent iron deficiency as a potentially modifiable contributor to adolescent cognitive impairment and outline a cautious approach to its assessment in oncology practice.
Materials and Methods
This focused narrative review draws on six selected publications addressing iron physiology, adolescent supplementation, cognitive outcomes, diagnostic evaluation, and cancer-associated anemia. It is not a systematic review and reports no original patient data or pooled effect estimates. Evidence was interpreted according to population, baseline anemia status, cognitive domain, and relevance to adolescent oncology. Absolute depletion of iron stores was distinguished from inflammation-related functional iron restriction, in which stored iron is insufficiently available to tissues. Adult oncology recommendations were treated as contextual guidance rather than validated pediatric protocols.
Iron supports mitochondrial energy production, neurotransmitter metabolism, and myelin maintenance, providing biological plausibility for cognitive effects before overt anemia. A randomized trial in nonanemic iron-deficient adolescent girls reported improvement in verbal learning and memory after supplementation. Broader synthesis suggests possible benefits in attention and concentration, but inconsistent outcomes and methodological variation limit confidence in generalized cognitive improvement. Direct evidence in adolescents with cancer remains insufficient.
Clinical assessment should integrate dietary history, menstrual or other bleeding, fatigue, school difficulties, and treatment exposure. Hemoglobin alone cannot exclude iron depletion. Low ferritin supports depleted stores, whereas inflammation can elevate ferritin and conceal deficiency. Transferrin saturation, C-reactive protein, and, where appropriate, reticulocyte hemoglobin or soluble transferrin receptor may improve interpretation. Thresholds require age- and context-sensitive application.
Management should address the underlying cause and confirm deficiency before replacement. Oral iron may be suitable when absorption and tolerance are adequate; intravenous treatment requires specialist judgment, particularly during active cancer therapy. Previous transfusions, possible iron overload, and competing explanations for cognitive symptoms must be considered. Changes in iron indices and symptoms should be monitored separately, because biochemical correction does not demonstrate cognitive recovery.
Latent iron deficiency is a plausible, treatable contributor to adolescent cognitive difficulties, not an established explanation for all cancer-related cognitive impairment. Targeted assessment is reasonable when clinical risk factors coexist with symptoms. Future studies should combine standardized cognitive testing, inflammation-adjusted iron assessment, and longitudinal follow-up to establish whether treatment offers benefits beyond correcting anemia or reducing fatigue.
1. Bruner, A. B., Joffe, A., Duggan, A. K., Casella, J. F., & Brandt, J. (1996). Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. The Lancet, 348(9033), 992–996.
2. Falkingham, M., Abdelhamid, A., Curtis, P., Fairweather-Tait, S., Dye, L., & Hooper, L. (2010). The effects of oral iron supplementation on cognition in older children and adults: A systematic review and meta-analysis. Nutrition Journal, 9, Article 4.
3. Beard, J. L. (2001). Iron biology in immune function, muscle metabolism and neuronal functioning. The Journal of Nutrition, 131(2), 568S–580S.
4. Camaschella, C. (2015). Iron-deficiency anemia. The New England Journal of Medicine, 372(19), 1832–1843.
5. Short, M. W., & Domagalski, J. E. (2013). Iron deficiency anemia: Evaluation and management. American Family Physician, 87(2), 98–104.
6. Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., & Jordan, K. (2018). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 29(Suppl. 4), iv96–iv110.